Bridge Biotherapeutics to Present Full Pipeline Updates at BIO 2022 International Convention


SEONGNAM, South Korea, May 25, 2022 /PRNewswire/ — Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is expected to give a complete company presentation on Thursday June 16 at the International Convention BIO 2022 which takes place in San Diego, CaliforniaBetween June 13 – 16, 2022.

Pavel Printsev, Biotherapeutic Bridge Business Development Manager, will provide insight into the business as well as the latest information on its clinical-stage assets:

  • BBT-401a Pellino-1 inhibitor for ulcerative colitis

  • BBT-877an autotaxin inhibitor for idiopathic pulmonary fibrosis

  • BBT-176a fourth-generation EGFR TKI for non-small cell lung cancer

  • BBT-207also a fourth-generation EGFR TKI for non-small cell lung cancer (about to begin clinical trials)

“We are delighted be able to give an in-person presentation at this year’s BIO International conference. We look forward to the opportunity to discuss our progress and partnership ambitions for therapies that will be treat serious diseases for which there are no viable treatment options,” said Pavel Printsev, Business Development Manager of Bridge Biothethe raputic.

To learn more about the session and Biotherapeutic Bridge, please visit the events page of our site to

  • What: A complete presentation of the company

  • When: Thursday June 1611:45 (PDT)

  • Or: Company Presentation Theater 3

  • Therapeutic Category: Multiple Therapeutic

About Bridge Biotherapeutics

Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotechnology company based in the Republic of Korea with offices in the United States and China. Founded in 2015, Bridge Biotherapeutics is engaged in the discovery and development of novel therapies for disease indications with significant unmet medical need, including cancer, ulcerative colitis and fibrotic diseases. The Company’s clinical pipeline includes BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S triple mutations. As 2022 dawns, the company is strengthening its strategic focus on fibrotic diseases and cancers. For more information, visit


Show original content:

SOURCEBridge Biotherapeutics, Inc.


About Author

Comments are closed.